CORDIS
EU research results

CORDIS

English EN
Transcranial brain stimulation as innovative therapy for chronic pediatric neuropsychiatric disorder – STIPED

Transcranial brain stimulation as innovative therapy for chronic pediatric neuropsychiatric disorder – STIPED

Objective

Due to lack of targeted interventions, compliance issues, insufficient effect sizes and a high non-responder rate to currently available interventions, there is an urgent need to develop innovative and new interventions for chronic paediatric neuropsychiatric disorders, such as Attention-Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). Transcranial direct current stimulation (tDCS) has been shown to be an innovative, effective and safe alternative treatment approach for neuropsychiatric disorders in adults. Here, for the first time, the effect of tDCS on core neurocognitive and behavioral outcomes will be proven in children and adolescents. First, effect sizes and safety of standard tDCS in the clinical setting targeting core brain regions and disorder specific cognitive tasks will be established by three phase-IIa randomized, double blind, sham-controlled studies in ADHD and ASD. Second, the impact of brain development and age-dependent anatomical / functional features on effects of tDCS will be studied systematically using methods of modern neurophysiology, neuroimaging and electric current modeling. This involves an additional phase-I clinical trial. Third, mechanisms of tDCS on brain function will be studied, and biomarkers will be developed in order to predict individual response to standard and individualized stimulation protocols. Finally, the applicability of tDCS in children and adolescents will be improved by developing an innovative personalized home-based treatment option in combination with a telemental health service, which will be tested by a fifth, phase-IIa clinical trial. Throughout the entire project, ethical concerns of the target population will be addressed. This project opens a new avenue for the application of tDCS as an alternative treatment for a great number of chronic neuropsychiatric disorders in children and adolescents and will allow flexible integration of tDCS in the daily routine of families.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

EVANGELISCHES KLINIKUM BETHEL GGMBH

Address

Kantensiek 11
33617 Bielefeld

Germany

Activity type

Research Organisations

EU Contribution

€ 644 260

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN

Germany

EU Contribution

€ 1 141 675

OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG

Germany

EU Contribution

€ 375 733,75

UNIVERSIDADE DE COIMBRA

Portugal

EU Contribution

€ 495 376,25

FUNDACAO DA FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA FP

Portugal

EU Contribution

€ 743,50

CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS

France

EU Contribution

€ 184 251,25

NEUROELECTRICS BARCELONA SL

Spain

EU Contribution

€ 765 625

STARLAB BARCELONA SL

Spain

EU Contribution

€ 378 125

ARTTIC

France

EU Contribution

€ 380 500

ZENTRUM FUER INTEGRATIVE PSYHIATRIE

Germany

EU Contribution

€ 262 031,25

FCIENCIAS.ID - ASSOCIACAO PARA A INVESTIGACAO E DESENVOLVIMENTO DE CIENCIAS

Portugal

EU Contribution

€ 629,65

REGION HOVEDSTADEN

Denmark

EU Contribution

€ 176 435,60

CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL

Germany

EU Contribution

€ 1 389 845

Project information

Grant agreement ID: 731827

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2021

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 6 195 231,25

  • EU contribution

    € 6 195 231,25

Coordinated by:

EVANGELISCHES KLINIKUM BETHEL GGMBH

Germany